The Eggplant Cancer Cure
A member of many scientific societies, Bill E. Cham, Ph.D., is frequently invited to speak at conferences on his research topics. His research interests cover a wide range of disciplines resulting in publication of over a hundred articles on topics ranging from pharmacology, iron metabolism, mineral research, lipidology and oncology. His reasearch in lipidology starting from test tube observations, have led to clinical trials in the USA for the treatment of atherosclerosis, HIV, and AIDS.
His work in oncology has produced Curaderm BEC5 for the treatment of skin cancers. Human clinical trials in Australia are currently underway to establish whether BEC can also treat terminal internal cancers effectively.
Dr. Cham’s research is acknowledged worldwide and many scientists are focused on extending his original discovery and research observations.
The Eggplant Cancer Cure
An Effective, Natural Solution to the Skin Cancer Epidemic
Skin cancer has become so prevalent that it is now more common world-wide than all other cancers combined and the most common form of cancer in the U.S., where one in five Americans and one in three Caucasians will develop some type of skin cancer during their lifetime.
Among men over age 50, skin cancer now ranks #1, ahead of prostate, lung and colon cancer, and its incidence is also greatly increasing in younger men and women. In the last 30 years, incidence of squamous cell carcinoma has quadrupled in younger individuals. During that time period, the percentage of women under age 40 with basal cell carcinoma has tripled as well, rendering younger women the fastest growing group of skin cancer patients.1
In Northern California, free skin cancer screening clinics conducted over a 3-year period revealed that 54% of the 374 people screened had precancerous or cancerous skin lesions.2
In 2008, more than 1 million basal cell carcinomas and 250,000 squamous cell carcinomas will be diagnosed. While these cancers both have a better than 95% cure rate, if detected and treated early, treatment is typically disfiguring.
Why? Because, until now, the treatments available for skin cancer have caused damage to healthy as well as cancerous skin cells, resulting in pigment loss and scarring. Today, thanks to Dr. Bill Cham’s 25 years of extensive research, we have a new and better option for basal and squamous cell carcinomas (and also for actinic keratoses, those unsightly precancerous skin lesions that afflict virtually everyone over 50).
Dr. Cham’s skin cancer solution, Curaderm BEC5, is a topically applied cream containing solasodine glycosides—phytochemicals derived from eggplant that penetrate and destroy only abnormal and cancerous skin cells, without damaging normal tissues. The result: full restoration of healthy skin.
The Eggplant Cancer Cure –A Treatment for Skin Cancer and New Hope for Other Cancers from Nature’s Pharmacy details Dr. Cham’s discovery of these cancer-removing phytochemicals, their mechanism of action, and the stringent research that has led to their formulation in an effective cure for actinic keratoses and basal and squamous skin cancers, Curaderm BEC5.
In addition to providing a thorough overview of the characteristics, causes and treatment options for actinic keratoses and non-melanoma skin cancers, The Eggplant Cancer Cure explains, both in simple English and scientifically precise language, exactly how Curaderm BEC5 works. Unaltered original photographs of numerous patients document the progression of treatment, evidencing Curaderm’s destruction of basal and squamous cell cancers—some several inches across—and their gradual replacement with healthy skin.
This book will arm you with the information you need to prevent and effectively treat non-melanoma skin cancers. Following is a brief summary of key points fully covered in The Eggplant Cancer Cure.
Non-Melanoma Skin Cancer Primer
Actinic keratoses (AKs), those small, crusty, rough, typically reddened patches—the result of prolonged exposure to sunlight—are not cancerous, but are a warning sign of potential skin cancer. In addition to being unsightly, if untreated, these abnormal skin growths on the skin’s top layer can invade deeper structures and evolve into malignant skin cancers. In the U.S., destruction of AKs is the single most commonly performed dermatologic procedure in the outpatient setting.
Basal cell carcinoma, cancer occurring in the basal cells (the cells that line the deepest layer of the skin’s outermost layer or epidermis), is the most common form of cancer. Easy to treat when caught early, basal cell carcinoma (BCC) is very unlikely to metastasize, although—until the development of Curaderm BEC5—treatment often caused scarring and disfigurement. BCC sometimes resembles psoriasis or eczema, typically appearing as a persistent open sore that doesn’t heal, a reddish patch, shiny mole-like or pink bump, or whitish scar-like area.
Squamous cell carcinoma occurs in the cells that compose most of the epidermis. The second most common form of skin cancer, SCC appears in over 200,000 individuals in the U.S. annually, causing about 1,900 deaths each year. SCC may look like a wart that crusts and occasionally bleeds; a persistent, scaly red patch with irregular borders that sometimes crusts or bleeds; or an open non-healing sore that bleeds and crusts.
The Eggplant Cancer Cure provides photographs that clearly illustrate each of these different variations in the appearance of actinic keratoses, basal and squamous cell carcinomas.
Melanoma, the most dangerous form of skin cancer, is a malignant tumor that originates in the melanocytes, the cells that produce the pigment melanin, which colors our skin, hair, and eyes. The majority of melanomas are black or brown, although some are skin-colored, pink, red, purple, blue or white. If recognized and treated early, melanoma is nearly 100% curable, but if not, can metastasize. Asymmetrical moles that are different shades of brown, tan or black and have uneven borders should be checked by your physician immediately. Fortunately, melanomas are much less common than basal or squamous cell carcinomas. Approximately 60,000 new cases of melanoma are identified annually, resulting in about 8,000 deaths. Early detection and surgical removal are the treatment of choice; Curaderm is not an effective treatment for melanoma.
What is Curaderm BEC5?
Curaderm BEC5 is a topical cream formulation containing a mixture of solasodine glycosides, active phytochemicals extracted from eggplant that selectively kill cancer cells without harming normal cells.
How does it work?
Other anti-cancer drugs kill cells by interfering with mitosis, the process through which cells divide and replicate. Cancer cells undergo mitosis much more frequently than normal cells, so killing all dividing cells causes the death of many more cancerous than normal cells, but these drugs kill not only cancer cells, but also normal cells while they are dividing.
Curaderm’s mechanism of action is different and allows it to kill cancer cells, and only cancer cells, regardless of whether they are dividing or “resting”. Cancer cells have large numbers of a specific receptor on their surface that recognizes and binds BEC, which is then drawn inside the cancer cell and taken up by its “stomach” (lysosomes). When the lysosomes digest BEC, solasodine is generated and causes the lysosome to rupture, spilling its contents—digestive enzymes—into the cell. The cancer cell’s own digestive enzymes then proceed to digest the cell, causing its death through apoptosis (more like an organized disassembly process than a death.) The fact that BEC kills cancer cells by triggering the natural process of apoptosis is key to its elegance: BEC preserves the natural healing processes for rebuilding the normal tissue that was lost to the cancer.
Normal cells either completely lack this receptor or have only an extremely small amount of it, so BEC cannot attach to normal cells.
How was it discovered?
Folklore among farmers in Australia, which has long reported that the crushing and application of a poultice of the fruit of a weed known as Devil’s Apple (Solanum linnaeanum) retards the progression of eye cancer in Hereford cattle, brought the plant to Dr. Cham’s attention. He then set out to identify possible active compounds in the plant and discovered that the active agent was the mixture of solasodine glycosides found in Devil’s Apple, publishing his research in 1987.
Knowing that Devil’s Apple belongs to the same family of plants as eggplant, potatoes and tomatoes, Dr. Cham then sought to determine if eggplant, a more readily cultivated plant worldwide, also contained solasodine glycosides. Further research not only led to Dr. Cham’s confirmation that BEC is also present in eggplant, but his development and patenting of a purified mixture of the active glycoalkaloids, which is now known as BEC.
What research has been done to verify Curaderm’s BEC5 effectiveness?
Twenty-five years of basic, pre-clinical and clinical research have now established that BEC, in a cream formulation at lower concentrations than are present in eggplant, effectively cures non-melanoma skin cancers.
After in vitro (test tube) studies demonstrated that BEC was effective against a wide spectrum of human cancer cell lines and was selectively killing cancer cells without harming normal cells, in vivo studies of mice, rats and horses established that BEC cured terminal tumors in animals.
The next stage of research involved a series of clinical trials with human participants. After Phase I clinical trials using a very small group of subjects, in which concentrations of BEC of up to 50% in a topical cream formulation were shown to be extremely safe (no systemic absorption, no adverse effects) and effective, Phase II clinical trials involving 129 patients confirmed BEC was safe and effective in a cream formulation. Larger Phase III trials of 232 patients were then conducted in Australia and multi-center hospitals in the United Kingdom.
Results of the Phase III trials determined that Curaderm BEC5 successfully cured non-melanoma skin cancers in 78% of patients when applied twice daily under occlusive dressing for 8 weeks. When treatment was extended to 12 weeks, cure rates were 100%! Patients were then followed for 5 years post treatment, and not a single recurrence of a treated lesion occurred.
Phase IV trials were then conducted to detect any rare or long-term adverse effects. After a 10 year-period during which 50,000 patients used Curaderm BEC5, only two experienced an adverse effect—dermatitis (reddening of the skin) at the site of Curaderm BEC5 application, which quickly went away when Curaderm BEC5 application was stopped.
Currently on-going clinical trials are evaluating the potential of the internal administration of the glycoalkaloids in BEC in humans suffering from terminal internal cancers.
Curaderm BEC5—An Ideal Skin Cancer Therapy
For the first time, with Curaderm BEC5, it is possible to eliminate skin cancer without harming surrounding healthy skin cells. Until now, the available anti-cancer drugs were neither selective nor able to eliminate skin cancer without harming normal skin.
Today, because of Dr. Cham’s rigorous research, we now have access to an ideal skin cancer therapy—one that when applied topically to an exposed skin cancer selectively destroys all the tumor cells without causing any damage to any surrounding healthy skin cells, has no adverse side effects, is much less expensive than other treatments, very simple to use, and, most importantly, works, restoring healthy, unblemished skin virtually every time.
The Eggplant Cancer Cure –A Treatment for Skin Cancer and
New Hope for Other Cancers from Nature’s Pharmacy
By Bill E. Cham, Ph.D.
Copyright © 2007
Smart Publications - ISBN: 1-890572-21-7
$24.95 - 132 pages, hardcover
Read book Review
Christenson LJ, Borrownman TA, Vachon CM, Tollefson MM, Otley CC, Weaver AL, Roenigk RK. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA. 2005;294:681-690. ↑
Swetter SM, Waddell BL, Vazquez MD, et al. Increased effectiveness of targeted skin cancer screening in the Veterans Affairs population of Northern California. Prev Med. 2003 Feb;36(2):164-71. PMID: 12590991. ↑
Lara Pizzorno is a member of the American Medical Writers Association with 25+ years of experience writing for physicians and the public, Lara is Editor for Longevity Medicine Review as well as Senior Medical Editor for SaluGenecists, Inc. Read more...
Lara Pizzorno, MDiv, MA, LMT
John Morgenthaler has been active in the field of nutritional medicine since 1986. Today, John travels the world looking for breakthrough nutraceuticals and anti-aging therapies. He also continues to publish cutting-edge nutrition and medical science books and periodicals. Read more...
John Morgenthaler, Publisher